RESUMEN

Dipyrone (DIP), also known as metamizole, is an over-the-counter analgesic used in Europe and Latin America. Evidence suggesting that inflammatory pain attenuation by DIP is associated with a direct impact on peripheral primary nociceptive neurons through the stimulation of nitric oxide signaling pathway. However, the molecular mechanism by which DIP activates this pathway remains unknown. The PI3Kγ/AKT signaling cascade activation is one of the well-known molecular mechanisms that promote nitric oxide production in sensory neurons. Herein, we investigated the role of the PI3Kγ/AKT signaling cascade in the context of peripheral analgesic effect of DIP. DIP was administered into PGE2 pre-sensitized paws of rats and mechanical hyperalgesia was determined using electronic von Frey test after 1 h. Nonselective or selective pharmacological inhibitors of PI3Kγ and AKT were also administered in DIP-treated rats under paws sensitized with PGE2. Intraplantar injection of DIP attenuated PGE2-induced hyperalgesia in a dose-dependent manner. Treatment with nonselective (wortmannin or LY294002) or selective (AS605240) pharmacological inhibitors of PI3Kγ reduced the peripheral antihypernociceptive effect of DIP. Consistently, AKT selective inhibitor also reversed analgesic DIP effects. Corroborating these data, we found that DIP induced AKT phosphorylation in cultured dorsal root ganglion neurons, which was prevented in the presence of PI3Kγ selective inhibitor. Taken together, these findings provide evidence that peripheral analgesic effect of DIP is dependent on the activation of PI3Kγ/AKT signaling pathway.

Asunto(s)

Analgésicos/farmacología , Dipirona/farmacología , Nociceptores/efectos de los fármacos , Dolor/prevención & control , Animales , Fosfatidilinositol 3-Quinasa Clase Ib/metabolismo , Masculino , Proteínas Proto-Oncogénicas c-akt/metabolismo , Ratas , Ratas Wistar

RESUMEN

Dipyrone (metamizole) is well-known for its powerful effect with central and peripheral activity. This meta-analysis involved articles published between 1973 and 2021, revealing that Brazil is the country which most published scientific articles relating the use of dipyrone in dogs, and this drug is widely recommended as an analgesic to control pain in cases of postoperative and cancer. Dipyrone is one of the favorite drugs used in small animal clinic in Brazil, and 12 commercial brands are available to use in dogs at doses among 25 to 50mg/kg for oral, intravenous and intramuscular administration. The effects of dipyrone may be potentiated when used in combination with other analgesic agents such as tramadol. In several studies, the occurrence of vomiting has been observed as an adverse effect, especially when the drug is used during surgical procedures, but metamizole has presented a low potential to cause gastric ulceration. The meta-analysis study of the use of dipyrone in dogs shows the clinical importance of this drug in Brazil, being an effective and safe medication, as long as it is used in the indicated dose of 25 mg/kg.(AU)

---

A dipirona (metamizol) é bem conhecida por seu poderoso efeito com atividade central e periférica. Esta meta-nálise envolveu estudos publicados entre os anos de 1973 a 2021, revelando que o Brasil é o país que mais publicou artigos científicos envolvendo o uso de dipirona em cães, sendo este fármaco amplamente recomendado como analgésico para controlar a dor em casos de câncer e dor pós-operatória. É um dos medicamentos preferidos da clínica médica de pequenos animais no Brasil. 12 marcas comerciais estão disponíveis para uso em cães em doses que variam de 25 a 50g para administração oral, intravenosa e intramuscular. Os efeitos da dipirona podem ser potencializados quando usada em combinação com outros analgésicos, como o tramadol. Em vários estudos, a ocorrência de vômito tem sido observada como efeito adverso, principalmente quando o medicamento é usado durante procedimentos cirúrgicos, mas tem baixo potencial para causar ulceração gástrica. O estudo de meta-análise do uso de dipirona em cães evidencia a importância do uso clínico deste fármaco no Brasil, sendo um medicamento eficaz e seguro para cães, desde que utilizada na dose indicada de 25 mg / kg.(AU)

Asunto(s)

Animales , Perros , Perros/fisiología , Dipirona/administración & dosificación , Dipirona/farmacología

RESUMEN

Dipyrone (metamizole) is well-known for its powerful effect with central and peripheral activity. This meta-analysis involved articles published between 1973 and 2021, revealing that Brazil is the country which most published scientific articles relating the use of dipyrone in dogs, and this drug is widely recommended as an analgesic to control pain in cases of postoperative and cancer. Dipyrone is one of the favorite drugs used in small animal clinic in Brazil, and 12 commercial brands are available to use in dogs at doses among 25 to 50mg/kg for oral, intravenous and intramuscular administration. The effects of dipyrone may be potentiated when used in combination with other analgesic agents such as tramadol. In several studies, the occurrence of vomiting has been observed as an adverse effect, especially when the drug is used during surgical procedures, but metamizole has presented a low potential to cause gastric ulceration. The meta-analysis study of the use of dipyrone in dogs shows the clinical importance of this drug in Brazil, being an effective and safe medication, as long as it is used in the indicated dose of 25 mg/kg.

---

A dipirona (metamizol) é bem conhecida por seu poderoso efeito com atividade central e periférica. Esta meta-nálise envolveu estudos publicados entre os anos de 1973 a 2021, revelando que o Brasil é o país que mais publicou artigos científicos envolvendo o uso de dipirona em cães, sendo este fármaco amplamente recomendado como analgésico para controlar a dor em casos de câncer e dor pós-operatória. É um dos medicamentos preferidos da clínica médica de pequenos animais no Brasil. 12 marcas comerciais estão disponíveis para uso em cães em doses que variam de 25 a 50g para administração oral, intravenosa e intramuscular. Os efeitos da dipirona podem ser potencializados quando usada em combinação com outros analgésicos, como o tramadol. Em vários estudos, a ocorrência de vômito tem sido observada como efeito adverso, principalmente quando o medicamento é usado durante procedimentos cirúrgicos, mas tem baixo potencial para causar ulceração gástrica. O estudo de meta-análise do uso de dipirona em cães evidencia a importância do uso clínico deste fármaco no Brasil, sendo um medicamento eficaz e seguro para cães, desde que utilizada na dose indicada de 25 mg / kg.

Asunto(s)

Animales , Perros , Perros/fisiología , Dipirona/administración & dosificación , Dipirona/farmacología

RESUMEN

BACKGROUND AND PURPOSE: While dipyrone is a widely used analgesic, its mechanism of action is not completely understood. Recently, we have reported that the dipyrone metabolite 4-aminoantipyrine (4-AA) reduces PGE2 -induced pain-related behaviour through cannabinoid CB1 receptors. Here, we ascertained, in naive and PGE2 -induced "inflamed" conditions, both in vivo and in vitro, the molecular mechanisms involved in the 4-AA-induced analgesic effects. EXPERIMENTAL APPROACH: The effect of local administration of 4-AA (160 µg per paw) on capsaicin (0.12 µg per paw) injection-induced pain-related behaviour and 4-AA's effect on 500-nM capsaicin-induced changes in intracellular calcium concentration ([Ca2+ ]i ) in cultured primary sensory neurons were assessed in vivo and in vitro, respectively. KEY RESULTS: 4-AA reduced capsaicin-induced nociceptive behaviour in naive and inflamed conditions through CB1 receptors. 4-AA (100 µM) reduced capsaicin-induced increase in [Ca2+ ]i in a CB1 receptor-dependent manner, when PGE2 was not present. Following PGE2 application, 4-AA (1-50 µM) increased the [Ca2+ ]i . Although 4-AA activated both TRPV1 and TRPA1 channels, increased [Ca2+ ]i was mediated through TRPV1 channels. Activation of TRPV1 channels resulted in their desensitisation. Blocking CB1 receptors reduced both the excitatory and desensitising effects of 4-AA. CONCLUSION AND IMPLICATIONS: CB1 receptor-mediated inhibition of TRPV1 channels and TRPV1-mediated Ca2+ -influx- and CB1 receptor-dependent desensitisation of TRPV1 channels contribute to the anti-nociceptive effect of 4-AA in naive and inflamed conditions respectively. Agonists active at both CB1 receptors and TRPV1 channels might be useful as analgesics, particularly in inflammatory conditions.

Asunto(s)

Dipirona , Canales Catiónicos TRPV , Analgésicos/farmacología , Capsaicina/farmacología , Dipirona/farmacología , Ganglios Espinales , Células Receptoras Sensoriales

RESUMEN

Central neuropathic pain is a common untreated symptom in progressive multiple sclerosis (PMS) and is associated with poor quality of life and interference with patients' daily activities. The neuroinflammation process and mitochondrial dysfunction in the PMS lesions generate reactive species. The transient potential receptor ankyrin 1 (TRPA1) has been identified as one of the major mechanisms that contribute to neuropathic pain signaling and can be activated by reactive compounds. Thus, the goal of our study was to evaluate the role of spinal TRPA1 in the central neuropathic pain observed in a PMS model in mice. We used C57BL/6 female mice (20-30 g), and the PMS model was induced by the experimental autoimmune encephalomyelitis (EAE) using mouse myelin oligodendrocyte glycoprotein (MOG35-55) antigen and CFA (complete Freund's adjuvant). Mice developed progressive clinical score, with motor impairment observed after 15 days of induction. This model induced mechanical and cold allodynia and heat hyperalgesia which were measured up to 14 days after induction. The hypersensitivity observed was reduced by the administration of selective TRPA1 antagonists (HC-030031 and A-967079, via intrathecal and intragastric), antioxidants (α-lipoic acid and apocynin, via intrathecal and intragastric), and TRPA1 antisense oligonucleotide (via intrathecal). We also observed an increase in TRPA1 mRNA levels, NADPH oxidase activity, and 4-hydroxinonenal (a TRPA1 agonist) levels in spinal cord samples of PMS-EAE induced animals. In conclusion, these results support the hypothesis of the TRPA1 receptor involvement in nociception observed in a PMS-EAE model in mice.

Asunto(s)

Encefalomielitis Autoinmune Experimental/complicaciones , Hiperalgesia/fisiopatología , Proteínas del Tejido Nervioso/fisiología , Neuralgia/fisiopatología , Nocicepción/fisiología , Médula Espinal/fisiopatología , Canal Catiónico TRPA1/fisiología , Acetanilidas/farmacología , Acetanilidas/uso terapéutico , Acetofenonas/farmacología , Analgésicos/farmacología , Analgésicos/uso terapéutico , Animales , Antipirina/análogos & derivados , Antipirina/farmacología , Antipirina/uso terapéutico , Dipirona/farmacología , Dipirona/uso terapéutico , Encefalomielitis Autoinmune Experimental/fisiopatología , Femenino , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/etiología , Ratones , Ratones Endogámicos C57BL , Glicoproteína Mielina-Oligodendrócito/inmunología , Glicoproteína Mielina-Oligodendrócito/toxicidad , NADPH Oxidasas/antagonistas & inhibidores , Proteínas del Tejido Nervioso/biosíntesis , Proteínas del Tejido Nervioso/genética , Neuralgia/tratamiento farmacológico , Neuralgia/etiología , Nocicepción/efectos de los fármacos , Oligonucleótidos Antisentido/farmacología , Estrés Oxidativo , Oximas/farmacología , Oximas/uso terapéutico , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/toxicidad , Pregabalina/farmacología , Pregabalina/uso terapéutico , Purinas/farmacología , Purinas/uso terapéutico , Canal Catiónico TRPA1/antagonistas & inhibidores , Canal Catiónico TRPA1/biosíntesis , Canal Catiónico TRPA1/genética , Ácido Tióctico/farmacología , Regulación hacia Arriba/efectos de los fármacos

RESUMEN

Pain is a classical sign of inflammation, and sensitization of primary sensory neurons (PSN) is the most important mediating mechanism. This mechanism involves direct action of inflammatory mediators such as prostaglandins and sympathetic amines. Pharmacologic control of inflammatory pain is based on two principal strategies: (i) non-steroidal anti-inflammatory drugs targeting inhibition of prostaglandin production by cyclooxygenases and preventing nociceptor sensitization in humans and animals; (ii) opioids and dipyrone that directly block nociceptor sensitization via activation of the NO signaling pathway. This review summarizes basic concepts of inflammatory pain that are necessary to understand the mechanisms of peripheral NO signaling that promote peripheral analgesia; we also discuss therapeutic perspectives based on the modulation of the NO pathway.

Asunto(s)

Antiinflamatorios no Esteroideos/farmacología , Dipirona/farmacología , Inflamación/prevención & control , Óxido Nítrico/metabolismo , Dolor/prevención & control , Transducción de Señal/efectos de los fármacos , Animales , Humanos , Inflamación/complicaciones , Inflamación/metabolismo , Dolor/etiología , Dolor/metabolismo , Prostaglandinas/metabolismo , Células Receptoras Sensoriales/efectos de los fármacos , Células Receptoras Sensoriales/metabolismo

RESUMEN

Tagetes lucida Cav. (Asteraceae) is an ancient medicinal plant commonly used to alleviate pain. Nevertheless, scientific studies validating this property are lacking in the literature. Animal models of pain were used to evaluate the antinociceptive and anti-inflammatory activities of T. lucida essential oil (TLEO) and a bioactive metabolite. The chemical constitution and possible toxicity of the extract and the mechanism of action of ß-caryophyllene were also explored. Temporal course curves and dose-response graphics were generated using TLEO (0.1-10 mg/kg or 3.16-31.62 mg/kg) and ß-caryophyllene (3.16-10 mg/kg). Metamizole (80 mg/kg) and indomethacin (20 mg/kg) were used as reference drugs in the formalin assay and writhing test in rats and mice, respectively. The ß-caryophyllene mechanism of action was explored in the presence of naloxone (1 mg/kg), flumazenil (10 mg/kg), WAY100635 (0.16 mg/kg), or nitro-l-arginine methyl ester (L-NAME) (20 mg/kg) in the formalin test in rats. GC/MS analysis demonstrated the presence of geranyl acetate (49.89%), geraniol (7.92%), and ß-caryophyllene (6.27%). Significant and dose-dependent antinociceptive response was produced by TLEO and ß-caryophyllene without the presence of gastric damage. In conclusion, ß-caryophyllene was confirmed as a bioactive compound in the T. lucida analgesic properties by involving the participation of receptors like opioids, benzodiazepines, and Serotonin 1A receptor (5-HT1A), as well as nitric oxide.

Asunto(s)

Antiinflamatorios/administración & dosificación , Aceites Volátiles/química , Dolor/tratamiento farmacológico , Sesquiterpenos Policíclicos/administración & dosificación , Tagetes/química , Animales , Antiinflamatorios/química , Antiinflamatorios/farmacología , Dipirona/administración & dosificación , Dipirona/farmacología , Modelos Animales de Enfermedad , Cromatografía de Gases y Espectrometría de Masas , Indometacina/administración & dosificación , Indometacina/farmacología , Masculino , Ratones , Óxido Nítrico/metabolismo , Dolor/metabolismo , Aceites de Plantas/química , Sesquiterpenos Policíclicos/química , Sesquiterpenos Policíclicos/farmacología , Ratas , Receptor de Serotonina 5-HT1A/metabolismo

RESUMEN

Dipyrone (metamizole), acting through its main metabolites 4-methyl-amino-antipyrine and 4-amino-antipyrine, has established analgesic, antipyretic, and spasmolytic pharmacological effects, which are mediated by poorly known mechanisms. In rats, intravenously administered dipyrone delays gastric emptying (GE) of liquids with the participation of capsaicin-sensitive afferent fibers. This effect seems to be mediated by norepinephrine originating from the sympathetic nervous system but not from the superior celiac-mesenteric ganglion complex, which activates ß2-adrenoceptors. In rats, in contrast to nonselective non-hormonal anti-inflammatory drugs, dipyrone protects the gastric mucosa attenuating the development of gastric ulcers induced by a number of agents. Clinically, it has been demonstrated that dipyrone is effective in the control of colic-like abdominal pain originating from the biliary and intestinal tracts. Since studies in humans and animals have demonstrated the presence of ß2-adrenoceptors in biliary tract smooth muscle and ß2-adrenoceptor activation has been shown to occur in dipyrone-induced delayed GE, it is likely that this kind of receptors may participate in the reduction of smooth muscle spasm of the sphincter of Oddi induced by dipyrone. There is no evidence that dipyrone may interfere with small bowel and colon motility, and the clinical results of its therapeutic use in intestinal colic appear to be due to its analgesic effect.

Asunto(s)

Ampirona/farmacología , Antiinflamatorios no Esteroideos/farmacología , Antipirina/farmacología , Dipirona/farmacología , Vaciamiento Gástrico/efectos de los fármacos , Animales , Bloqueo Nervioso Autónomo , Dipirona/administración & dosificación , Ratas , Ratas Wistar

RESUMEN

This experiment was carried out aiming to assess walking manner and speed of broiler chickens with different gait scores (GS), with or without sound stimulus, and with or without administration of analgesic. To that end, 1,000 birds were evaluated by the GS test and 74 were selected for walking speed analyses. Weight at slaughter and breast yield values were obtained for comparisons. Walking speed analyses, both with and without analgesic and with and without stimulus were performed. Non-parametric statistics was applied to the GS data that did not meet the assumptions of the statistical model (normality and homogenicity) using Fisher's exact test according to the data behavior (P<0.05). The analyses of data on speed, weight at slaughter, and breast yield were evaluated by ANOVA and compared by Tukey's test (P<0.05). Walking speed differed after acoustic stimulus with or without administration of metamizole sodium. Body weight was also different in each GS. It is thus concluded that the birds may feel discomfort when their GS is higher than 0, but that such discomfort may be suppressed when they are stimulated to walk.

Asunto(s)

Analgésicos/farmacología , Marcha/fisiología , Animales , Peso Corporal/efectos de los fármacos , Pollos , Dipirona/farmacología , Marcha/efectos de los fármacos , Programas Informáticos

RESUMEN

Dipyrone (metamizole), acting through its main metabolites 4-methyl-amino-antipyrine and 4-amino-antipyrine, has established analgesic, antipyretic, and spasmolytic pharmacological effects, which are mediated by poorly known mechanisms. In rats, intravenously administered dipyrone delays gastric emptying (GE) of liquids with the participation of capsaicin-sensitive afferent fibers. This effect seems to be mediated by norepinephrine originating from the sympathetic nervous system but not from the superior celiac-mesenteric ganglion complex, which activates β2-adrenoceptors. In rats, in contrast to nonselective non-hormonal anti-inflammatory drugs, dipyrone protects the gastric mucosa attenuating the development of gastric ulcers induced by a number of agents. Clinically, it has been demonstrated that dipyrone is effective in the control of colic-like abdominal pain originating from the biliary and intestinal tracts. Since studies in humans and animals have demonstrated the presence of β2-adrenoceptors in biliary tract smooth muscle and β2-adrenoceptor activation has been shown to occur in dipyrone-induced delayed GE, it is likely that this kind of receptors may participate in the reduction of smooth muscle spasm of the sphincter of Oddi induced by dipyrone. There is no evidence that dipyrone may interfere with small bowel and colon motility, and the clinical results of its therapeutic use in intestinal colic appear to be due to its analgesic effect.

Asunto(s)

Animales , Ratas , Antiinflamatorios no Esteroideos/farmacología , Ampirona/farmacología , Antipirina/farmacología , Dipirona/farmacología , Vaciamiento Gástrico/efectos de los fármacos , Bloqueo Nervioso Autónomo , Dipirona/administración & dosificación , Ratas Wistar

RESUMEN

Atropine (AT) and dipyrone (Dp) induce a delay of gastric emptying (GE) of liquids in rats by inhibiting muscarinic receptors and activating ß2-adrenergic receptors, respectively. The objective of the present study was to determine the effects of pretreatment with AT and Dp, given alone or in combination, on the effect of hypoglycemia in the liquid GE in rats. Male Wistar adult rats (280-310 g) were pretreated intravenously with AT, Dp, AT plus Dp or their vehicle and then treated 30 min later with iv insulin or its vehicle (n=8-10 animals/group). Thirty min after treatment, GE was evaluated by determining, in awake rats, the percent gastric retention (%GR) of a saline meal labeled with phenol red administered by gavage. The results indicated that insulin induced hypoglycemia in a dose-dependent manner resulting in a significant reduction in %GR of liquid only at the highest dose tested (1 U/kg). Pretreatment with AT significantly increased %GR in the rats treated with 1 U/kg insulin. Surprisingly, after pretreatment with AT, the group treated with the lowest dose of insulin (0.25 U/kg) displayed significantly lower %GR compared to its control (vehicle-treated group), which was not seen in the non-pretreated animals. Pretreatment with Dp alone at the dose of 40 mg/kg induced an increase in %GR in both vehicle and 0.25 U/kg-treated rats. A higher dose of Dp alone (80 mg/kg) significantly reduced the effect of a marked hypoglycemia induced by 1 U/kg of insulin on GE while in combination with AT the effect was completely abolished. The results with AT suggest that moderate hypoglycemia may render the inhibitory mechanisms of GE ineffective while Dp alone and in combination with AT significantly overcame the effect of hypoglycemia on GE.

Asunto(s)

Antiinflamatorios no Esteroideos/farmacología , Atropina/farmacología , Dipirona/farmacología , Vaciamiento Gástrico/efectos de los fármacos , Hipoglucemia/fisiopatología , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Atropina/administración & dosificación , Dipirona/administración & dosificación , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Hipoglucemia/inducido químicamente , Hipoglucemiantes/administración & dosificación , Insulina/administración & dosificación , Masculino , Modelos Animales , Premedicación , Ratas , Ratas Wistar

RESUMEN

Atropine (AT) and dipyrone (Dp) induce a delay of gastric emptying (GE) of liquids in rats by inhibiting muscarinic receptors and activating β2-adrenergic receptors, respectively. The objective of the present study was to determine the effects of pretreatment with AT and Dp, given alone or in combination, on the effect of hypoglycemia in the liquid GE in rats. Male Wistar adult rats (280-310 g) were pretreated intravenously with AT, Dp, AT plus Dp or their vehicle and then treated 30 min later with iv insulin or its vehicle (n=8-10 animals/group). Thirty min after treatment, GE was evaluated by determining, in awake rats, the percent gastric retention (%GR) of a saline meal labeled with phenol red administered by gavage. The results indicated that insulin induced hypoglycemia in a dose-dependent manner resulting in a significant reduction in %GR of liquid only at the highest dose tested (1 U/kg). Pretreatment with AT significantly increased %GR in the rats treated with 1 U/kg insulin. Surprisingly, after pretreatment with AT, the group treated with the lowest dose of insulin (0.25 U/kg) displayed significantly lower %GR compared to its control (vehicle-treated group), which was not seen in the non-pretreated animals. Pretreatment with Dp alone at the dose of 40 mg/kg induced an increase in %GR in both vehicle and 0.25 U/kg-treated rats. A higher dose of Dp alone (80 mg/kg) significantly reduced the effect of a marked hypoglycemia induced by 1 U/kg of insulin on GE while in combination with AT the effect was completely abolished. The results with AT suggest that moderate hypoglycemia may render the inhibitory mechanisms of GE ineffective while Dp alone and in combination with AT significantly overcame the effect of hypoglycemia on GE.

Asunto(s)

Animales , Masculino , Ratas , Antiinflamatorios no Esteroideos/farmacología , Atropina/farmacología , Dipirona/farmacología , Vaciamiento Gástrico/efectos de los fármacos , Hipoglucemia/fisiopatología , Antiinflamatorios no Esteroideos/administración & dosificación , Atropina/administración & dosificación , Dipirona/administración & dosificación , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Hipoglucemia/inducido químicamente , Hipoglucemiantes/administración & dosificación , Insulina/administración & dosificación , Modelos Animales , Premedicación , Ratas Wistar

RESUMEN

There is evidence for participation of peripheral β-adrenoceptors in delayed liquid gastric emptying (GE) induced in rats by dipyrone (Dp), 4-aminoantipyrine (AA), and antipyrine (At). The present study aimed to determine whether β-adrenoceptors are involved in delayed GE induced by phenylpyrazole derivatives and the role of the prevertebral sympathetic nervous system in this condition. Male Wistar rats weighing 220-280 g were used in the study. In the first experiment rats were intravenously pretreated with vehicle (V), atenolol 30 mg/kg (ATE, β1-adrenergic antagonist), or butoxamine 25 mg/kg (BUT, β2-adrenergic antagonist). In the second experiment, rats were pretreated with V or SR59230A 2 mg/kg (SRA, β3-adrenergic antagonist). In the third experiment, rats were subjected to surgical resection of the celiac-superior mesenteric ganglion complex or to sham surgery. The groups were intravenously treated with saline (S), 240 µmol/kg Dp, AA, or At, 15 min after pretreatment with the antagonists or V and nine days after surgery. GE was determined 10 min later by measuring the percentage of gastric retention (%GR) of saline labeled with phenol red 10 min after gavage. The %GR (means±SE, n=6) values indicated that BUT abolished the effect of Dp (BUT+Dp vs V+Dp: 35.0%±5.1% vs 56.4%±2.7%) and At (BUT+At vs V+At: 33.5%±4.7% vs 52.9%±2.6%) on GE, and significantly reduced (P<0.05) the effect of AA (BUT+AA vs V+AA: 48.0%±5.0% vs 65.2%±3.8%). ATE, SRA, and sympathectomy did not modify the effects of treatments. These results suggest that β2-adrenoceptor activation occurred in delayed liquid gastric emptying induced by the phenylpyrazole derivatives dipyrone, 4-aminoantipyrine, and antipyrine. Additionally, the released neurotransmitter did not originate in the celiac-superior mesenteric ganglion complex.

Asunto(s)

Animales , Masculino , Antagonistas Adrenérgicos beta/farmacología , Antiinflamatorios no Esteroideos/farmacología , Antipirina/administración & dosificación , Ganglionectomía , Vaciamiento Gástrico/efectos de los fármacos , Receptores Adrenérgicos beta/metabolismo , Antagonistas Adrenérgicos beta/administración & dosificación , Ampirona/farmacología , Atenolol/farmacología , Butoxamina/farmacología , Dipirona/farmacología , Relación Dosis-Respuesta a Droga , Ganglios Simpáticos/cirugía , Modelos Animales , Propanolaminas/farmacología , Ratas Wistar , Sistema Nervioso Simpático/efectos de los fármacos

RESUMEN

There is evidence for participation of peripheral ß-adrenoceptors in delayed liquid gastric emptying (GE) induced in rats by dipyrone (Dp), 4-aminoantipyrine (AA), and antipyrine (At). The present study aimed to determine whether ß-adrenoceptors are involved in delayed GE induced by phenylpyrazole derivatives and the role of the prevertebral sympathetic nervous system in this condition. Male Wistar rats weighing 220-280 g were used in the study. In the first experiment rats were intravenously pretreated with vehicle (V), atenolol 30 mg/kg (ATE, ß1-adrenergic antagonist), or butoxamine 25 mg/kg (BUT, ß2-adrenergic antagonist). In the second experiment, rats were pretreated with V or SR59230A 2 mg/kg (SRA, ß3-adrenergic antagonist). In the third experiment, rats were subjected to surgical resection of the celiac-superior mesenteric ganglion complex or to sham surgery. The groups were intravenously treated with saline (S), 240 µmol/kg Dp, AA, or At, 15 min after pretreatment with the antagonists or V and nine days after surgery. GE was determined 10 min later by measuring the percentage of gastric retention (%GR) of saline labeled with phenol red 10 min after gavage. The %GR (means±SE, n=6) values indicated that BUT abolished the effect of Dp (BUT+Dp vs V+Dp: 35.0%±5.1% vs 56.4%±2.7%) and At (BUT+At vs V+At: 33.5%±4.7% vs 52.9%±2.6%) on GE, and significantly reduced (P<0.05) the effect of AA (BUT+AA vs V+AA: 48.0%±5.0% vs 65.2%±3.8%). ATE, SRA, and sympathectomy did not modify the effects of treatments. These results suggest that ß2-adrenoceptor activation occurred in delayed liquid gastric emptying induced by the phenylpyrazole derivatives dipyrone, 4-aminoantipyrine, and antipyrine. Additionally, the released neurotransmitter did not originate in the celiac-superior mesenteric ganglion complex.

Asunto(s)

Antagonistas Adrenérgicos beta/farmacología , Antiinflamatorios no Esteroideos/farmacología , Antipirina/administración & dosificación , Ganglionectomía , Vaciamiento Gástrico/efectos de los fármacos , Receptores Adrenérgicos beta/metabolismo , Antagonistas Adrenérgicos beta/administración & dosificación , Ampirona/farmacología , Animales , Atenolol/farmacología , Butoxamina/farmacología , Dipirona/farmacología , Relación Dosis-Respuesta a Droga , Ganglios Simpáticos/cirugía , Masculino , Modelos Animales , Propanolaminas/farmacología , Ratas Wistar , Sistema Nervioso Simpático/efectos de los fármacos

RESUMEN

Naringenin is a flavonoid widely consumed by humans that present anti-inflammatory activity and low toxicity. Recently, the analgesic effect of naringenin has been demonstrated in neuropathic pain models. Herein, we tested the analgesic effects of naringenin in several models of inflammatory pain. Mice received treatment with naringenin (16.7-150 mg/kg, per oral), or with the controls anti-inflammatory drugs indomethacin (5 mg/kg, intraperitoneal) or dipyrone (80 mg/kg, intraperitoneal) prior the inflammatory stimuli injection. For acute pain, we used acetic acid- and PBQ-induced visceral pain (abdominal writhings), and formalin-, capsaicin-, and CFA-induced paw flinching and licking. By using an electronic version of von Frey filaments, we also investigated the effects of naringenin in pain intensity to a mechanical stimulus (mechanical hyperalgesia) after carrageenan, capsaicin, CFA, or PGE2 intraplantar injection. Naringenin (50 mg/kg) reduced acute pain behaviors induced by all tested stimuli, including both phases of formalin test, suggesting a direct nociceptor modulatory effect of this compound besides its anti-inflammatory activity. Accordingly, naringenin also inhibited the increased sensitivity to mechanical stimulus induced by carrageenan, capsaicin, and PGE2. Daily treatment with naringenin during 7 days also reduced CFA-induced mechanical hyperalgesia without gastric or hepatic toxicity. The mechanisms of naringenin involve the inhibition of carrageenan-induced oxidative stress, hyperalgesic cytokines (IL-33, TNF-α, and IL-1ß) production and NF-κB activation in the paw skin. Naringenin also activated the analgesic NO-cyclic GMP-PKG-ATP sensitive K(+) channel signaling pathway to inhibit carrageenan-induced mechanical hyperalgesia and neutrophil recruitment. These results suggest that naringenin inhibits both inflammatory pain and neurogenic inflammation.

Asunto(s)

Analgésicos/farmacología , Flavanonas/farmacología , Hiperalgesia/tratamiento farmacológico , Dolor Visceral/tratamiento farmacológico , Animales , Citocinas/metabolismo , Dipirona/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Hiperalgesia/metabolismo , Indometacina/farmacología , Inyecciones Intraperitoneales , Canales KATP/metabolismo , Hígado/efectos de los fármacos , Masculino , Ratones , Actividad Motora/efectos de los fármacos , FN-kappa B/metabolismo , Neutrófilos/efectos de los fármacos , Nociceptores/efectos de los fármacos , Estómago/efectos de los fármacos , Dolor Visceral/metabolismo

RESUMEN

The purpose of the present study was to evaluate the effect of common pediatric liquid medicines on surface roughness and tooth structure loss and to evaluate the pH values of these medicines at room and cold temperatures in vitro. Eighty-four bovine enamel blocks were divided into seven groups (n = 12): G1-Alivium®, G2-Novalgina®, G3-Betamox®, G4-Clavulin®, G5-Claritin®, G6-Polaramine® and G7-Milli-Q water (negative control). The pH was determined and the samples were immersed in each treatment 3x/day for 5 min. 3D non-contact profilometry was used to determine surface roughness (linear Ra, volumetric Sa) and the Gap formed between treated and control areas in each block. Scanning electron microscopy (SEM) and energy dispersive spectrometry (EDS) were also performed. The majority of liquid medicines had pH ≤ 5.50. G1, G4, and G5 showed alterations in Ra when compared with G7 (p < 0.05). According to Sa and Gap results, only G5 was different from G7 (p < 0.05). Alteration in surface was more evident in G5 SEM images. EDS revealed high concentrations of carbon, oxygen, phosphorus, and calcium in all tested groups. Despite the low pH values of all evaluated medicines, only Alivium®, Clavulin®, and Claritin® increased linear surface roughness, and only Claritin® demonstrated the in vitro capacity to produce significant tooth structure loss.

Asunto(s)

Analgésicos/química , Antibacterianos/química , Esmalte Dental/efectos de los fármacos , Combinación Amoxicilina-Clavulanato de Potasio/química , Combinación Amoxicilina-Clavulanato de Potasio/farmacología , Animales , Bovinos , Clorfeniramina/química , Clorfeniramina/farmacología , Frío , Esmalte Dental/química , Dipirona/química , Dipirona/farmacología , Pruebas de Dureza , Concentración de Iones de Hidrógeno , Loratadina/química , Loratadina/farmacología , Microscopía Electrónica de Rastreo , Espectrometría por Rayos X , Estadísticas no Paramétricas , Propiedades de Superficie/efectos de los fármacos

RESUMEN

Abstract The purpose of the present study was to evaluate the effect of common pediatric liquid medicines on surface roughness and tooth structure loss and to evaluate the pH values of these medicines at room and cold temperatures in vitro. Eighty-four bovine enamel blocks were divided into seven groups (n = 12): G1-Alivium®, G2-Novalgina®, G3-Betamox®, G4-Clavulin®, G5-Claritin®, G6-Polaramine® and G7-Milli-Q water (negative control). The pH was determined and the samples were immersed in each treatment 3x/day for 5 min. 3D non-contact profilometry was used to determine surface roughness (linear Ra, volumetric Sa) and the Gap formed between treated and control areas in each block. Scanning electron microscopy (SEM) and energy dispersive spectrometry (EDS) were also performed. The majority of liquid medicines had pH ≤ 5.50. G1, G4, and G5 showed alterations in Ra when compared with G7 (p < 0.05). According to Sa and Gap results, only G5 was different from G7 (p < 0.05). Alteration in surface was more evident in G5 SEM images. EDS revealed high concentrations of carbon, oxygen, phosphorus, and calcium in all tested groups. Despite the low pH values of all evaluated medicines, only Alivium®, Clavulin®, and Claritin® increased linear surface roughness, and only Claritin® demonstrated the in vitro capacity to produce significant tooth structure loss.

Asunto(s)

Animales , Bovinos , Analgésicos/química , Antibacterianos/química , Esmalte Dental/efectos de los fármacos , Combinación Amoxicilina-Clavulanato de Potasio/química , Combinación Amoxicilina-Clavulanato de Potasio/farmacología , Frío , Clorfeniramina/química , Clorfeniramina/farmacología , Esmalte Dental/química , Dipirona/química , Dipirona/farmacología , Pruebas de Dureza , Concentración de Iones de Hidrógeno , Loratadina/química , Loratadina/farmacología , Microscopía Electrónica de Rastreo , Espectrometría por Rayos X , Estadísticas no Paramétricas , Propiedades de Superficie/efectos de los fármacos

RESUMEN

OBJECTIVE: To compare the effects of dipyrone, meloxicam, and of the combination of these drugs on hemostasis in dogs. DESIGN: Prospective, blinded, randomized crossover study. SETTING: Research laboratory at a veterinary teaching hospital. ANIMALS: Six adult dogs. INTERVENTIONS: Animals received 4 intravenous treatments with 15-day washout intervals: control (physiological saline, 0.1 mL/kg), meloxicam (0.2 mg/kg), dipyrone (25 mg/kg), and dipyrone-meloxicam (25 and 0.2 mg/kg, respectively). A jugular catheter was placed for drug injection and for collecting samples for whole blood platelet aggregation (WBPA) and thromboelastometry assays at baseline, 1, 2, 3, 5, and 8 hours after treatment administration. The percent change from baseline of lag time and of the area under the curve (AUC) of impedance changes in response to collagen-induced platelet activation were recorded during WBPA. Thromboelastometry-derived parameters included clotting time, clot formation time, alpha-angle, and maximum clot firmness. The buccal mucosal bleeding time was evaluated by a blinded observer at baseline, 1, 3, and 5 hours after treatment injection. MEASUREMENTS AND MAIN RESULTS: No significant changes in WBPA and thromboelastometry were recorded in the control treatment. Dipyrone significantly (P < 0.05) increased the lag time for 2 hours and decreased the AUC for 3 hours after injection. Meloxicam did not alter WBPA. Dipyrone-meloxicam significantly increased lag time for 2 hours and decreased the AUC for 5 hours after treatment injection. Experimental treatments did not differ from the control treatment for thromboelastometry and buccal mucosal bleeding time. CONCLUSIONS: While meloxicam does not alter hemostasis by the methods evaluated, dipyrone inhibits platelet aggregation for up to 3 hours. Meloxicam-dipyrone combination causes more prolonged inhibition of platelet function than dipyrone alone. Decreased platelet aggregation induced by dipyrone and dipyrone-meloxicam does not appear to impact the viscoelastic properties of the blood clot nor increase the risk of bleeding in dogs without preexisting hemostatic disorders.

Asunto(s)

Dipirona/farmacología , Agregación Plaquetaria/efectos de los fármacos , Tiazinas/farmacología , Tiazoles/farmacología , Animales , Pruebas de Coagulación Sanguínea/veterinaria , Estudios Cruzados , Dipirona/administración & dosificación , Perros , Esquema de Medicación , Quimioterapia Combinada , Femenino , Hemostasis/efectos de los fármacos , Infusiones Intravenosas , Masculino , Meloxicam , Estudios Prospectivos , Tiazinas/administración & dosificación , Tiazoles/administración & dosificación , Tromboelastografía/veterinaria

RESUMEN

AIMS: We evaluated the role of adrenergic systems on the peripheral antinociception induced by dipyrone and diclofenac. Mainmethods: The rat pawpressure test, inwhich sensitivity is increased by intraplantar injection of prostaglandin E2, was used to examine the peripheral effects of locally administered drugs. KEY FINDINGS: Dipyrone (10, 20 and 40 µg) and diclofenac (5, 10 and 20 µg) administered locally into the right paw elicited a dose-dependent antinociceptive effect, which was demonstrated to be local; the injection of drugs into the ipsilateral and contralateral hindpaws demonstrated an effect only in the ipsilateral paw because only the treated paw produced an antinociceptive effect. To test the adrenergic system, we used guanethidine (30 mg/kg) to deplete noradrenalin from noradrenergic vesicles. Guanethidine antagonized the peripheral antinociception induced by diclofenac and dipyrone. Yohimbine (2.5, 5, 10, or 20 µg/paw) a nonselective α2-adrenergic receptor antagonist antagonized the peripheral antinociception induced by diclofenac (20 µg/paw) and dipyrone (40 µg/paw). Rauwolscine (Rau; 10, 15, 20 µg), a selective α2C-adrenoreceptor, was able to block the peripheral antinociception induced by NSAIDs. The other specific α2A,B and D-adrenoreceptor antagonists (BRL 44480, imiloxan and RX 821002, respectively) did not modify the peripheral antinociception. However, prazosin (0.5, 1, and 2 µg/paw), an α1 receptor antagonist, and propranolol (0.3, 0.6 or 1.2 µg/paw), a ß-adrenoreceptor antagonist, antagonized the antinociception induced by diclofenac (20 µg/paw) and dipyrone (40 µg/paw). SIGNIFICANCE: Dipyrone and diclofenac produce peripheral antinociception, which involves the release of NA and interaction with α1, α2C and ß-adrenoreceptors.

Asunto(s)

Antiinflamatorios no Esteroideos/farmacología , Diclofenaco/farmacología , Dipirona/farmacología , Receptores Adrenérgicos alfa/efectos de los fármacos , Receptores Adrenérgicos beta/efectos de los fármacos , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Diclofenaco/administración & dosificación , Dipirona/administración & dosificación , Relación Dosis-Respuesta a Droga , Guanetidina/farmacología , Masculino , Norepinefrina/metabolismo , Prazosina/administración & dosificación , Prazosina/farmacología , Ratas , Ratas Wistar , Receptores Adrenérgicos alfa/metabolismo , Receptores Adrenérgicos beta/metabolismo , Yohimbina/administración & dosificación , Yohimbina/farmacología

RESUMEN

Background: There is a gap between the number of patients requiring a renal allograft and the number of potential deceased donors (DD). One alternative is using allografts from non-related living donors (NRLD). Aim: To compare survival and complications of renal allograft recipients from DD, related living donors (RLD) and NRLD. Material and Methods: Observational study of a cohort of renal allograft recipients. Of 253 transplants performed in a Chilean region between 1981 and 2003, 20 patients received and allograft from a NRLD. Graft and patient survival of these patients were compared with those of 93 patients receiving an allograft from a related living donor and 140 receiving it from a DD. Patients were followed for 10 years or until death or dialysis requirement. Results: No significant differences between groups in graft and patient survival, deaths with a functioning graft or return to dialysis were observed. Receptors of DD had more hospital admissions during the first years after receiving the graft, usually due to infections. Also a delayed graft function was more common among them. Glomerular filtration rate ten years after the graft was similar among the three groups. Conclusions: No differences in graft or patient survival was observed between patients receiving a renal allograft from NRLD, RLD or DD.

Asunto(s)

Animales , Femenino , Ratones , Ratas , Analgésicos , Antiinflamatorios no Esteroideos , Niacinamida/análogos & derivados , Niacinamida/farmacología , Amidas/farmacología , Carragenina , Dipirona/farmacología , Edema/inducido químicamente , Edema/tratamiento farmacológico , Formaldehído , Calor , Isomerismo , Actividad Motora/efectos de los fármacos , Dimensión del Dolor/efectos de los fármacos , Ácidos Picolínicos/farmacología , Poli(ADP-Ribosa) Polimerasas/antagonistas & inhibidores , Equilibrio Postural/efectos de los fármacos , Ratas Wistar